Healthcare
Live Price
Offline$37.06
+0.00% today
1Y Change
-19.54%
Window
Jun 27, 2025 → Jun 23, 2026
Coverage: 151 bars · Jun 27, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
COSMOS Pharmaceutical Corporation (CSMYF) is a Healthcare stock with a market cap of $488.86B. The stock last traded around $37.06 and down 19.5% across the available one-year price window (Jun 27, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of +26.7%, a dividend yield of 1.2%. What stands out right now is revenue +4.8%, EPS +26.7%, free cash flow -35.3% with operating margin 3.8% and ROIC 8.9%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 15.6 and price/sales 0.5. Stock Foundry combines CSMYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSMYF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSMYF Max Drawdown
-23.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CSMYF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$726.4B
-3.8% YoY
FY Net Income
$27.2B
+17.3% YoY
Free Cash Flow
$1.8B
+116.0% YoY
Revenue Growth
+4.8%
EPS Growth
+26.7%
Gross Margin
20.9%
Net Margin
2.9%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1011.4B | 965.0B | 827.7B | 755.4B | 726.4B |
| Gross Profit | 213.3B | 188.3B | 168.7B | 151.4B | 145.1B |
| Operating Income | 40.4B | 31.5B | 30.1B | 29.8B | 33.1B |
| EBITDA | 64.9B | 53.7B | 50.2B | 48.2B | 52.4B |
| Net Income | 31.0B | 24.5B | 23.8B | 23.2B | 27.2B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 57.0B | 52.3B | 45.9B | 37.4B | 55.1B |
| Total Assets | 524.8B | 476.5B | 421.0B | 363.1B | 341.3B |
| Total Liabilities | 267.3B | 245.1B | 209.9B | 172.5B | 170.7B |
| Shareholder Equity | 257.5B | 231.4B | 211.1B | 190.5B | 170.6B |
| Total Debt | 50.0B | 34.1B | 18.2B | 9.4B | 10.4B |
| Net Debt | -7.1B | -18.2B | -27.7B | -27.9B | -44.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
27.9B
-13.4% YoY
Capital Expenditures
26.1B
+40.1% YoY
Free Cash Flow
1.8B
+116.0% YoY
Key ratios
Gross Margin
20.9%
Operating Margin
3.8%
Net Margin
2.9%
ROE
11.8%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.